COMMUNIQUÉS West-GlobeNewswire

BrainStorm to Host Business Update Conference Call
07/03/2019
Tuesday, March 12th at 8.30am EDT NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating [...]
PDMR Dealing
07/03/2019
LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Helsinn initiates two new global Phase III studies with anamorelin
07/03/2019
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and [...]
About acquisition of significant shareholding
07/03/2019
On 20th of February 20, 2019 JSC Olainfarm has received a notification by Signe Baldere-Sildedze natural guardian of shareholder Anna Emīlija Maligina regarding increased material shareholding up till 7.8% from share [...]
AltoInvest purchases 131,000 warrants to be converted into C-RAD shares
07/03/2019
C-RAD today announces that AltoInvest purchased 131,000 warrants from C-RAD employees. The warrants are part of the employee warrant program approved by the Annual Shareholder Meeting in 2016. The warrants entitle [...]
Pixium Vision highlights conclusions of its KOL Meeting: Experts confirm PRIMA’s promises and potential to treat dry-AMD
07/03/2019
PRIMA, an unprecedented, innovative and evolutive “brain-machine” interface in ophthalmology PRIMA, bionic vision solution designed for advanced atrophic dry-AMD PRIMA clinical performance to date exceeded initial [...]
Pixium Vision présente les conclusions de son KOL meeting : les experts réaffirment les promesses de PRIMA et son intérêt dans la DMLA sèche
07/03/2019
PRIMA, une interface cerveau-machine inédite, innovante et évolutive en ophtalmologie PRIMA, une solution de vision bionique adaptée à la forme avancée de DMLA sèche PRIMA, des performances cliniques à ce jour [...]
L'essai clinique de Phase 2 sur le bermekimab montre une nouvelle norme de soins potentielle pour le traitement de l'hidrasadénite suppurée (HS), avec une réduction significative de la douleur sans associer d’antibiotiques
07/03/2019
- Avantage thérapeutique significatif obtenu, que les patients aient, ou non, déjà échoué au traitement avec un médicament biologique existant autorisé par la FDA. - 61 à 63 % des patients ont obtenu un score HiSCR [...]
ShockWave Announces Pricing of Initial Public Offering
07/03/2019
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public [...]
La collaboration entre Crown Bioscience et The Jackson Laboratory permet un accès mondial au modèle murin FATZO
07/03/2019
La collaboration continue facilite la distribution mondiale de l’obésité, des maladies métaboliques et du modèle NASH ainsi que l’approvisionnement prioritaire à la plateforme mondiale de maladies cardiovasculaires, de [...]
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
07/03/2019
BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
MRI Interventions, Inc. to Announce Fourth Quarter and Full Year 2018 Results on March 11
06/03/2019
IRVINE, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene [...]
Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members to Executive Leadership Team
06/03/2019
Accomplished Industry Leaders Join ICT to Spearhead U.S. Clinical Development Efforts ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing [...]
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
06/03/2019
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends [...]
Rockwell Medical, Inc. to Discuss Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
06/03/2019
WIXOM, Mich., March 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2018 fourth quarter and full year financial [...]
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
06/03/2019
– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 – – ILLUMINATE-206 Trial Expected to Initiate Q2 2019 – – Chief Medical Officer Dr. Joanna [...]
INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7
06/03/2019
PHOENIX, March 06, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced [...]
Nephros to Report Fourth Quarter and Year End 2018 Financial Results on March 12th, 2019
06/03/2019
SOUTH ORANGE, NJ, March 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
06/03/2019
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end 2018; February 2019 [...]

Pages